NAMS Menopause Certification Exam 2026/2027 | Complete Practice
Questions, Correct Answers & Detailed Rationales
Question 1 How is natural menopause clinically defined in retrospective
medical evaluation?
• A. Complete cessation of menses for 6 consecutive months
associated with elevated follicle-stimulating hormone (FSH) levels
• B. Permanent cessation of menses for 12 consecutive months
without other pathological or physiological cause
• C. The final menstrual period preceded by 3 years of irregular
oligomenorrhea
• D. Surgical removal of both ovaries regardless of menstrual history
Correct Answer: B. Permanent cessation of menses for 12
consecutive months without other pathological or physiological
cause
Detailed Rationale: Natural menopause is diagnosed
retrospectively after a woman has experienced 12 consecutive
months of amenorrhea in the absence of other biological or
pathological causes.
Question 2 Which hormonal marker rises significantly during the
menopausal transition due to the loss of negative feedback from the
aging ovary?
• A. Inhibin B
• B. Anti-Müllerian hormone (AMH)
, • C. Follicle-Stimulating Hormone (FSH)
• D. Estradio
l Correct Answer: C. Follicle-Stimulating Hormone (FSH)
Detailed Rationale: As ovarian follicular reserve diminishes, levels
of inhibin B and AMH decline, reducing negative feedback on the
pituitary gland and causing a marked elevation in serum FSH
levels.
Question 3 What is considered the most effective first-line systemic
medical therapy for moderate-to-severe vasomotor symptoms (VMS) in
a healthy woman under age 60 or within 10 years of menopause onset
who has no contraindications?
• A. Low-dose selective serotonin reuptake inhibitors (SSRIs)
• B. Menopausal hormone therapy (MHT)
• C. Gabapentin
• D. Phytoestrogens and soy isoflavones
Correct Answer: B. Menopausal hormone therapy (MHT)
Detailed Rationale: Systemic MHT remains the gold standard and
most effective treatment for moderate-to-severe vasomotor
symptoms, providing substantial relief and benefits that generally
outweigh risks for women under 60 or within 10 years of onset.
Question 4 Why must a woman with an intact uterus who is prescribed
systemic estrogen therapy also be prescribed a progestogen?
• A. To prevent bone mineral density loss in the spine
, • B. To prevent endometrial hyperplasia and significantly reduce the
risk of endometrial carcinoma
• C. To accelerate the therapeutic reduction of hot flashes
• D. To prevent breast tenderness and fibrocystic changes
Correct Answer: B. To prevent endometrial hyperplasia and
significantly reduce the risk of endometrial carcinoma
Detailed Rationale: Unopposed systemic estrogen stimulates
endometrial proliferation, leading to a high risk of endometrial
hyperplasia and cancer. Adding a progestogen provides
endometrial protection.
Question 5 Which of the following clinical conditions represents an
absolute contraindication to systemic menopausal hormone therapy?
• A. Controlled essential hypertension
• B. Active or personal history of breast cancer
• C. Mild asymptomatic hyperlipidemia
• D. History of treated gestational diabetes
Correct Answer: B. Active or personal history of breast cancer
, Detailed Rationale: A history of hormone-sensitive malignancies,
such as breast cancer, is an absolute contraindication to systemic
MHT due to the risk of stimulating tumor recurrence.
Question 6 Which non-hormonal medication class contains agents
specifically FDA-approved for the treatment of moderate-to-severe
vasomotor symptoms associated with menopause?
• A. Tricyclic antidepressants (e.g., amitriptyline)
• B. Neurokinin 3 (NK3) receptor antagonists (e.g., fezolinetant)
• C. Benzodiazepines (e.g., alprazolam)
• D. Beta-blockers (e.g., propranolol)
Correct Answer: B. Neurokinin 3 (NK3) receptor antagonists (e.g.,
fezolinetant)
Detailed Rationale: Fezolinetant is a non-hormonal neurokinin 3
receptor antagonist specifically designed and FDA-approved to treat
moderate-to-severe vasomotor symptoms by blocking neurokinin B
signaling in the thermoregulatory center.
Question 7 What is the preferred initial pharmacotherapy for a
postmenopausal woman experiencing moderate-to-severe
genitourinary syndrome of menopause (GSM) characterized primarily
by dyspareunia and vaginal dryness without vasomotor symptoms?
• A. Oral estrogen-progestogen combined therapy
• B. Low-dose vaginal estrogen therapy
Questions, Correct Answers & Detailed Rationales
Question 1 How is natural menopause clinically defined in retrospective
medical evaluation?
• A. Complete cessation of menses for 6 consecutive months
associated with elevated follicle-stimulating hormone (FSH) levels
• B. Permanent cessation of menses for 12 consecutive months
without other pathological or physiological cause
• C. The final menstrual period preceded by 3 years of irregular
oligomenorrhea
• D. Surgical removal of both ovaries regardless of menstrual history
Correct Answer: B. Permanent cessation of menses for 12
consecutive months without other pathological or physiological
cause
Detailed Rationale: Natural menopause is diagnosed
retrospectively after a woman has experienced 12 consecutive
months of amenorrhea in the absence of other biological or
pathological causes.
Question 2 Which hormonal marker rises significantly during the
menopausal transition due to the loss of negative feedback from the
aging ovary?
• A. Inhibin B
• B. Anti-Müllerian hormone (AMH)
, • C. Follicle-Stimulating Hormone (FSH)
• D. Estradio
l Correct Answer: C. Follicle-Stimulating Hormone (FSH)
Detailed Rationale: As ovarian follicular reserve diminishes, levels
of inhibin B and AMH decline, reducing negative feedback on the
pituitary gland and causing a marked elevation in serum FSH
levels.
Question 3 What is considered the most effective first-line systemic
medical therapy for moderate-to-severe vasomotor symptoms (VMS) in
a healthy woman under age 60 or within 10 years of menopause onset
who has no contraindications?
• A. Low-dose selective serotonin reuptake inhibitors (SSRIs)
• B. Menopausal hormone therapy (MHT)
• C. Gabapentin
• D. Phytoestrogens and soy isoflavones
Correct Answer: B. Menopausal hormone therapy (MHT)
Detailed Rationale: Systemic MHT remains the gold standard and
most effective treatment for moderate-to-severe vasomotor
symptoms, providing substantial relief and benefits that generally
outweigh risks for women under 60 or within 10 years of onset.
Question 4 Why must a woman with an intact uterus who is prescribed
systemic estrogen therapy also be prescribed a progestogen?
• A. To prevent bone mineral density loss in the spine
, • B. To prevent endometrial hyperplasia and significantly reduce the
risk of endometrial carcinoma
• C. To accelerate the therapeutic reduction of hot flashes
• D. To prevent breast tenderness and fibrocystic changes
Correct Answer: B. To prevent endometrial hyperplasia and
significantly reduce the risk of endometrial carcinoma
Detailed Rationale: Unopposed systemic estrogen stimulates
endometrial proliferation, leading to a high risk of endometrial
hyperplasia and cancer. Adding a progestogen provides
endometrial protection.
Question 5 Which of the following clinical conditions represents an
absolute contraindication to systemic menopausal hormone therapy?
• A. Controlled essential hypertension
• B. Active or personal history of breast cancer
• C. Mild asymptomatic hyperlipidemia
• D. History of treated gestational diabetes
Correct Answer: B. Active or personal history of breast cancer
, Detailed Rationale: A history of hormone-sensitive malignancies,
such as breast cancer, is an absolute contraindication to systemic
MHT due to the risk of stimulating tumor recurrence.
Question 6 Which non-hormonal medication class contains agents
specifically FDA-approved for the treatment of moderate-to-severe
vasomotor symptoms associated with menopause?
• A. Tricyclic antidepressants (e.g., amitriptyline)
• B. Neurokinin 3 (NK3) receptor antagonists (e.g., fezolinetant)
• C. Benzodiazepines (e.g., alprazolam)
• D. Beta-blockers (e.g., propranolol)
Correct Answer: B. Neurokinin 3 (NK3) receptor antagonists (e.g.,
fezolinetant)
Detailed Rationale: Fezolinetant is a non-hormonal neurokinin 3
receptor antagonist specifically designed and FDA-approved to treat
moderate-to-severe vasomotor symptoms by blocking neurokinin B
signaling in the thermoregulatory center.
Question 7 What is the preferred initial pharmacotherapy for a
postmenopausal woman experiencing moderate-to-severe
genitourinary syndrome of menopause (GSM) characterized primarily
by dyspareunia and vaginal dryness without vasomotor symptoms?
• A. Oral estrogen-progestogen combined therapy
• B. Low-dose vaginal estrogen therapy
